Positive data for Roche's I-O-chemo combo in small cell lung cancer

25 September 2018
2019_biotech_test_vial_discovery_big

Detailed results from the IMpower133 study suggest Roche (ROG: SIX) is poised to steal a march on immuno-oncology rivals in the relatively small population of small cell lung cancer patients.

Fleshing out headline data released earlier in the year, Roche says a drug cocktail of Tecentriq (atezolizumab) plus carboplatin and etoposide beat chemotherapy alone, with overall survival rates of 12.3 months against 10.3 months.

Earlier this month, US rival Merck & Co (NYSE: MRK) won approval from European regulators for Keytruda (pembrolizumab) plus chemo in the larger, more lucrative, non-small cell lung cancer indication.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology